Image of Dr Michael Dickinson

Prof Michael Dickinson MBBS (Hons) D.MedSc FRACP FRCPA manages all types of blood-related conditions including benign conditions causing abnormal blood counts, anaemia, bleeding disorders, blood clots, abnormal proteins in the blood, and enlarged lymph nodes. He is recognised globally for his expertise in lymphoma and in new therapies including CAR-T cell treatment and new immunotherapies. He treats all cancers of the blood system which include lymphoma, myeloma, myelodysplastic syndromes, and leukaemia. 

Prof Dickinson is an academic haematologist, and the Lead Clinician for Aggressive Lymphoma at Peter MacCallum Cancer Centre. He runs a programme of early phase clinical trials, with a special focus on B and T-cell lymphoma, and new targeted therapies.

Immunotherapy has now become a standard treatment option for many types of blood cancers and Prof Dickinson has led the development of CAR-T cells in lymphoma, and their implementation in Australia.  He is an expert in phase 1 and later stage trials. Professor Dickinson treated the first patients globally in the trials of glofitamab (bispecific antibody for lymphoma, he is the lead author of the NEJM paper), epigenetic agents (BET inhibitors), YTB323 (rapcabtagene autoleucel), ELARA (CAR-T registration trial for follicular lymphoma). His team were the first to use the CAR-T cell treatments Yescarta (Axicabtagene ciloleucel), Kymriah (tisagenlecleucel) and Tecartus (brexucabtagene autoleucel)in trials and commercially in Australia.

Prof Dickinson has worked in the Cabrini Medical system since 2011 and has worked with A/Prof Kenealy, Dr Herbert, and A/Prof Wolf since 2007. 

He is a Fellow of the Royal Australasian College of Physicians and Royal College of Pathologists of Australasia, Associate Professor at the University of Melbourne. Prof Dickinson Chairs the Lymphoma Working Party of the  Australasian Leukaemia and Lymphoma Group (ALLG), is a member of the ALLG Scientific Advisory Committee, and is a member the Australasian Lymphoma Alliance (ALA). He is a clinical advisor to the patient support group Lymphoma Australia, and is a member of the National Blood Cancer Taskforce.

Prof Dickinson has over 120 publications in peer-reviewed clinical journals, including in New England Journal of Medicine, Nature Medicine, the Journal of Clinical Oncology and Blood. He is an author on national and international treatment guidelines for lymphoma.

Although he enjoys academic medicine, his greatest professional satisfaction comes from making individual patients feel better. He believes in research-led clinical care, and placing a patient’s individual circumstances to the fore when developing a treatment plan that is not only evidence-based, but which is also right for them.


Key Publications:



1. Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F, Trněný M, Wu S-J, Cartron G, Hertzberg M, Sureda A, Perez-Callejo D, Lundberg L, Relf J, Dixon M, Clark E, Humphrey K, Hutchings M. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England Journal of Medicine 2022;387(24):2220-2231. DOI: 10.1056/NEJMoa2206913.

2. Dickinson MJ, Barba P, Jäger U, Shah NN, Blaise D, Briones J, Shune L, Boissel N, Bondanza A, Mariconti L, Marchal A-L, Quinn DS, Yang J, Price A, Sohoni A, Treanor LM, Orlando EJ, Mataraza J, Davis J, Lu D, Zhu X, Engels B, Moutouh-de Parseval L, Brogdon JL, Moschetta M, Flinn IW. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development. Cancer Discovery 2023;13(9):1982-1997. DOI: 10.1158/2159-8290.Cd-22-1276.

3. Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil LJ, Thieblemont C, Ursu R, Bartlett NL, Nachar VR, Weiss J, Osterson J, Patel K, Brody JD, Abramson JS, Lunning MA, Shah NN, Ayed A, Kamdar M, Parsons BM, Caimi P, Flynn IW, Herrera AF, Sharman JP, McKenna M, Armand P, Kahl BS, Smith SM, Zelenetz AD, Budde LE, Hutchings M, Phillips TJ, Dickinson M. Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy. Blood 2024. DOI: 10.1182/blood.2023022432.

4. Dickinson M, Briones J, Herrera AF, González-Barca E, Ghosh N, Cordoba R, Rutherford SC, Bournazou E, Labriola-Tompkins E, Franjkovic I, Chesne E, Brouwer-Visser J, Lechner K, Brennan B, Nüesch E, DeMario M, Rüttinger D, Kornacker M, Hutchings M. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood Advances 2021;5(22):4762-4770. DOI: 10.1182/bloodadvances.2021004619.

5. Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales M-A, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. New England Journal of Medicine 2023;389(2):148-157. DOI: 10.1056/NEJMoa2301665.

6. Westin JR, Locke FL, Dickinson M, Ghobadi A, Elsawy M, van Meerten T, Miklos DB, Ulrickson ML, Perales MA, Farooq U, Wannesson L, Leslie L, Kersten MJ, Jacobson CA, Pagel JM, Wulf G, Johnston P, Rapoport AP, Du L, Vardhanabhuti S, Filosto S, Shah J, Snider JT, Cheng P, To C, Oluwole OO, Sureda A. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma. Clinical Cancer Research 2023;29(10):1894-1905. DOI: 10.1158/1078-0432.CCR-22-3136.

7. Sales C, Anderson MA, Kuznetsova V, Rosenfeld H, Malpas CB, Roos I, Dickinson M, Harrison S, Kalincik T. Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: A single-centre cohort study. Eur J Neurol 2023. DOI: 10.1111/ene.16174.

8. Minson AG, Hamad N, Cheah CY, Tam CS, Blombery P, Westerman DA, Ritchie DS, Morgan H, Holzwart N, Lade S, Anderson MA, Khot A, Seymour JF, Robertson MR, Caldwell I, Ryland G, Saghebi J, Sabahi Z, Xie J, Koldej RM, Dickinson M. CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study. Blood 2023. DOI: 10.1182/blood.2023021306.

9. Minson A, Hamad N, Di Ciaccio P, Talaulikar D, Ku M, Ratnasingam S, Cheah C, Yannakou CK, Bishton M, Ng ZY, Agrawal S, McQuillan A, Johnston A, Choong E, Wong K, McQuillan J, Beekman A, Hawkes E, Dickinson M. Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom. British Journal of Haematology 2023. DOI: 10.1111/bjh.19179.

10. Lew TE, Minson A, Dickinson M, Handunnetti SM, Blombery P, Khot A, Anderson MA, Ritchie D, Tam CS, Seymour JF. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. The Lancet Haematology 2023;10(2):e142-e154. DOI: 10.1016/s2352-3026(22)00355-6.

11. Dawson MA, Borthakur G, Huntly BJP, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass JL, Kamdar M, Mateos M-V, Tovar N, Yeh P, Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A, Kremer BE, Dickinson M. A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. Clinical Cancer Research 2023;29(4):711-722. DOI: 10.1158/1078-0432.Ccr-22-1284.

12. Campbell BA, Brown R, Lambertini A, Hofman MS, Bressel M, Seymour JF, Wirth A, MacManus M, Dickinson M. Are dynamic or fixed FDG‐PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B‐cell lymphoma undergoing autologous haematopoietic stem cell transplantation? British Journal of Haematology 2023;201(3):502-509. DOI: 10.1111/bjh.18644.

13. Amatya B, Dickinson M, Khan F. Factors associated with long-term functional and psychosocial outcomes in patients with non-Hodgkin lymphoma. J Rehabil Med 2023;55:jrm004816. DOI: 10.2340/jrm.v55.4816.

14. Zinzani PL, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, de Oliveira JSR, Buccheri V, Perini GF, Dickinson M, McDonald A, Özcan M, Sekiguchi N, Zhu Y, Raut M, Saretsky TL, Nahar A, Kuruvilla J. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood Advances 2022;6(2):590-599. DOI: 10.1182/bloodadvances.2021004970.

15. Wight J, Hamad N, Campbell BA, Ku M, Lee K, Rose H, Armytage T, Latimer M, Lee HP, Lee ST, Dickinson M, Khor R, Verner E. Diffuse large B‐cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Intern Med J 2022;52(9):1609-1623. DOI: 10.1111/imj.15533.

16. Tam CS, Ho PJ, Purtill D, Blyth E, Butler J, Dickinson M, Harrison S. Fitness criteria for Australian patients referred for chimeric antigen receptor T‐cell therapy. Intern Med J 2022;52(8):1454-1456. DOI: 10.1111/imj.15868.

17. Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nature Medicine 2022;28(4):735-742. DOI: 10.1038/s41591-022-01731-4.

18. Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. New England Journal of Medicine 2022;386(7):640-654. DOI: 10.1056/NEJMoa2116133.

19. Dowling MR, Dickinson M. Post CAR-T cytopenia: poorly understood and clinically challenging. Leukemia & Lymphoma 2022;63(8):1774-1776. DOI: 10.1080/10428194.2022.2095631.

20. Bröske A-ME, Korfi K, Belousov A, Wilson S, Ooi C-H, Bolen CR, Canamero M, Alcaide EG, James I, Piccione EC, Carlile DJ, Dimier N, Umaña P, Bacac M, Weisser M, Dickinson M. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. Blood Advances 2022;6(3):1025-1037. DOI: 10.1182/bloodadvances.2021005954.

21. Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong Y-L, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. New England Journal of Medicine 2022;386(7):629-639. DOI: 10.1056/NEJMoa2116596.

22. Selim AG, Minson A, Blombery P, Dickinson M, Harrison SJ, Anderson MA. CAR-T cell therapy: practical guide to routine laboratory monitoring. Pathology 2021;53(3):408-415. DOI: 10.1016/j.pathol.2021.02.002.

23. Minson A, Dickinson M. Glofitamab CD20-TCB bispecific antibody. Leukemia & Lymphoma 2021;62(13):3098-3108. DOI: 10.1080/10428194.2021.1953016.

24. Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LM, Goncalves I, de Oliveira JSR, Buccheri V, Perini GF, Goldschmidt N, Kriachok I, Dickinson M, Komarnicki M, McDonald A, Ozcan M, Sekiguchi N, Zhu Y, Nahar A, Marinello P, Zinzani PL. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. The Lancet Oncology 2021;22(4):512-524. DOI: 10.1016/s1470-2045(21)00005-x.

25. Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martinez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Broske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umana P, Moore T, Weisser M, Dickinson MJ. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021;39(18):1959-1970. DOI: 10.1200/JCO.20.03175.

26. Gould C, Lickiss J, Kankanige Y, Yerneni S, Lade S, Gandhi MK, Chin C, Yannakou CK, Villa D, Slack GW, Markham JF, Tam CS, Nelson N, Seymour JF, Dickinson M, Neeson PJ, Westerman D, Blombery P. Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. British Journal of Haematology 2021;195(1):113-118. DOI: 10.1111/bjh.17789.

27. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nature Medicine 2021;28(2):325-332. DOI: 10.1038/s41591-021-01622-0.

28. Cochrane T, Campbell BA, Gangatharan SA, Latimer M, Khor R, Christie DRH, Gilbertson M, Ratnasingam S, Palfreyman E, Lee HP, Trotman J, Hertzberg M, Dickinson M. Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Intern Med J 2021;51(12):2119-2128. DOI: 10.1111/imj.15503.

29. Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, Batlevi CL, Campbell P, Ribrag V, Damaj GL, Dickinson M, Jurczak W, Kazmierczak M, Opat S, Radford J, Schmitt A, Yang J, Whalen J, Agarwal S, Adib D, Salles G. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. The Lancet Oncology 2020;21(11):1433-1442. DOI: 10.1016/s1470-2045(20)30441-1.

30. Di Ciaccio P, McCaughan G, Trotman J, Ho PJ, Cheah CY, Gangatharan S, Wight J, Ku M, Quach H, Gasiorowski R, Polizzotto MN, Prince HM, Mulligan S, Tam CS, Gregory G, Hapgood G, Spencer A, Dickinson M, Latimer M, Johnston A, Armytage T, Lee C, Cochrane T, Berkhahn L, Weinkove R, Doocey R, Harrison SJ, Webber N, Lee HP, Chapman S, Campbell BA, Gibbs SDJ, Hamad N. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Intern Med J 2020;50(6):667-679. (Article) (In English). DOI: 10.1111/imj.14859.

31. Chin CK, Lim KJ, Lewis K, Jain P, Qing Y, Feng L, Cheah CY, Seymour JF, Ritchie D, Burbury K, Tam CS, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Samaniego F, Flowers CR, Nastoupil LJ, Dickinson MJ. Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study. British Journal of Haematology 2020;191(5):806-815. DOI: 10.1111/bjh.17072.

32. Wight JC, Yue M, Keane C, Johnston A, Linton K, Chin C, Wai SH, Talaulikar D, Gasiorowski R, Cheah CY, Gregory GP, Dickinson M, Minson A, Coombes C, Ku M, Lam S, Hawkes EA. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B‐cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. British Journal of Haematology 2019;187(2):174-184. DOI: 10.1111/bjh.16064.

33. Opat S, Dickinson M, Cheah CY, Tam C, Boulos J, Thorburn AN, Trotman J. Management of patients with follicular lymphoma treated first line with obinutuzumab. Asia-Pac J Clin Oncol 2019;15(S3):3-11. (Article) (In English). DOI: 10.1111/ajco.13153.

34. Markham JF, Yerneni S, Ryland GL, Leong HS, Fellowes A, Thompson ER, De Silva W, Kumar A, Lupat R, Li J, Ellul J, Fox S, Dickinson M, Papenfuss AT, Blombery P. CNspector: a web-based tool for visualisation and clinical diagnosis of copy number variation from next generation sequencing. Scientific Reports 2019;9(1):6426. DOI: 10.1038/s41598-019-42858-8.

35. Gregory GP, Dickinson M, Yannakou CK, Wong J, Blombery P, Corboy G, Kats L, Crozier TME, Kumar B, Prince HM, Opat SS, Shortt J. Rapid and durable complete remission of refractory AITL with azacitidine treatment in absence of TET2 mutation or concurrent MDS. HemaSphere 2019;3(2) (Article) (In English). DOI: 10.1097/HS9.0000000000000187.

36. Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella MSO, Burgess P, Ramos PM, Choi J, Platzbecker U, investigators Ss. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood 2018;132(25):2629-2638. DOI: 10.1182/blood-2018-06-855221.

37. Yeh P, Dickinson M, Ftouni S, Hunter T, Sinha D, Wong SQ, Agarwal R, Vedururu R, Doig K, Fong CY, Blombery P, Westerman D, Dawson MA, Dawson S-J. Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. Blood 2017;129(12):1685-1690. DOI: 10.1182/blood-2016-09-740308.

38. Dickinson M, Irving L, Hofman M. Early warning signs: FDG-PET to diagnose bleomycin toxicity. Leukemia & Lymphoma 2017;58(5):1016-1018. DOI: 10.1080/10428194.2016.1277387.

39. Reis B, Jukofsky L, Chen G, Martinelli G, Zhong H, So WV, Dickinson MJ, Drummond M, Assouline S, Hashemyan M, Theron M, Blotner S, Lee JH, Kasner M, Yoon SS, Rueger R, Seiter K, Middleton SA, Kelly KR, Vey N, Yee K, Nichols G, Chen LC, Pierceall WE. Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. Haematologica 2016;101(5):e185-e188. DOI: 10.3324/haematol.2015.139717.

40. Burbury KL, Dickinson M, Westerman DA, Prince HM. Prevention of thromboembolism in myeloma: expanding the tool-box of assays to predict the risk? Leukemia & Lymphoma 2015;56(12):3246-3247. DOI: 10.3109/10428194.2015.1055487.

41. Villa D, George A, Seymour JF, Toze CL, Crump M, Lee C, Buckstein R, Stewart DA, MacDonald D, Foley R, Xenocostas A, Sabloff M, Chua N, Couture F, Larouche JF, Cohen S, Savage KJ, Connors JM, Panzarella T, Carney DA, Dickinson M, Kuruvilla J. Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma. Biology of Blood and Marrow Transplantation 2014;20(11):1813-1818. DOI: 10.1016/j.bbmt.2014.07.015.

42. Lewin J, Dickinson M, Voskoboynik M, Collins M, Ritchie D, Toner G. High‐dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients. Intern Med J 2014;44(8):771-778. (In Eng). DOI: 10.1111/imj.12486.

43. Cheah CY, Seymour JF, Dickinson M. Ongoing challenge of optimal patient selection for CNS prophylaxis in patients with non-Hodgkin lymphoma. International Journal of Hematologic Oncology 2014;3(3):189-201. (In English). DOI: 10.2217/ijh.14.15.

44. Tam CS, Herschtal A, Dickinson M, George A, Seymour JF. Chemotherapy versus autologous stem-cell transplantation for the treatment of transformed follicular lymphoma in the rituximab era. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(25):3166-7. (In eng). DOI: 10.1200/JCO.2013.50.2245.

45. Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K, Shin M, Wall DM, Hönemann D, Gambell P, Westerman DA, Haurat J, Westwood JA, Scott AM, Kravets L, Dickinson M, Trapani JA, Smyth MJ, Darcy PK, Kershaw MH, Prince HM. Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia. Molecular Therapy 2013;21(11):2122-2129. DOI: 10.1038/mt.2013.154.

46. Wong E, Seymour JF, Kenealy M, Westerman D, Herbert K, Dickinson M. Treatment of chronic myelomonocytic leukemia with azacitidine. Leukemia & Lymphoma 2012;54(4):878-880. (Comment Letter) (In eng). DOI: 10.3109/10428194.2012.730615.